Immutep Limited - ADR
IMMP
Get informed when a big investor buys or sells
+ FollowMarket Cap$23.58M
Close$
$0.02
99.2% downside
Current Fair Value
99.2% downsideOvervalued by 99.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $23.58 Million |
|---|---|
| Enterprise Value | $-44,249,850.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-10.7 |
| Beta | 2.31 |
| Outstanding Shares | 7,368,606 |
Return
| Return on Equity | -229.50% |
|---|---|
| Return on Assets | -169.59% |
| Return on Invested Capital | -217.89% |
Valuation & Multiples
| P/E Ratio | -0.43 |
|---|---|
| PEG | 4.04 |
| Price to Sales | 1.59 |
| Price to Book Ratio | 0.4 |
| Enterprise Value to Revenue | -2.04 |
| Enterprise Value to EBIT | 0.29 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$6.85 M
Average shareholder expectationNext Earnings Call
Expected Date
February 25, 2027
EPS Estimate
$-1.43
Average shareholder expectationRevenue Estimate
$1.43 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 210.94% |
|---|---|
| Total Calls | 171,800▲ 1242.19% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.13%▼ 0.64% |
|---|---|
| Total Invested | $692,001▼ 24.48% |
| Investors Holding | 25▼ 3.00% |
ESG Score
No data
About Immutep Limited
57 employees
CEO: Marc Voigt Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP32...